Dominic Hollamby | Vice Chairman
Rothschild

Dominic is a Vice Chairman of Rothschild in London and also holds the position of Global Head of Healthcare. He has been at Rothschild since 1998. As an experienced M&A practitioner focused on the healthcare industry, he has a long track record of completed healthcare transactions. Within the pharma / generics sector, Dominic has advised, inter alia,  Specifar on their sale to Watson Pharmaceuticals for €400m (2011)  BTG plc on their £177m acquisition of Biocompatibles (2010)  Mepha Group on their sale to Cephalon for US$590m (2010)  Herbacos-Bofarma on their sale to Recordati SpA (2009)  Marken on their sale to Apax Partners for £975m (2009)  The Board of Zentiva NV on its defence in relation to the €2.3bn offer by Sanofi-Aventis (2008)  Almirall on their IPO (2007)  Polpharma on the aborted merger with Gedeon Richter (2007)  Almirall on the €376m acquisition of Hermal from Reckitt Benckiser PLC (2007)  Schwarz Pharma AG on their €4.4bn takeover by UCB SA (2006)  Dr Reddy’s Laboratories on their €480 acquisition of betapharm  Sale of Viatris Group to Meda AB for €750m (2005)  Cephalon on their $360m acquisition of Zeneus Pharma (2005)  Recordati SpA on their acquisition of Mercle GmbH’s branded pharmaceuticals business (2005) Prior to joining Rothschild, Dominic was a Partner with Andersen and he spent one year seconded to HM Treasury and Department of Health establishing the private finance initiative (PFI) within the NHS during 1993/4. Dominic is a UK Chartered Accountant and read Chemistry at Oxford University.